ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $27,336 | +24.3% | 674 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $22,000 | -18.5% | 674 | -14.1% | 0.00% | 0.0% |
| Q2 2022 | $27,000 | -55.0% | 785 | -13.9% | 0.00% | -50.0% |
| Q4 2021 | $60,000 | +9.1% | 912 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $55,000 | -31.2% | 912 | -5.5% | 0.00% | -50.0% |
| Q2 2021 | $80,000 | +29.0% | 965 | +1.5% | 0.00% | 0.0% |
| Q1 2021 | $62,000 | -22.5% | 951 | -9.7% | 0.00% | -20.0% |
| Q4 2020 | $80,000 | +110.5% | 1,053 | +18.0% | 0.01% | +66.7% |
| Q3 2020 | $38,000 | 0.0% | 892 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $38,000 | +52.0% | 892 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $25,000 | -55.4% | 892 | 0.0% | 0.00% | -50.0% |
| Q4 2019 | $56,000 | +133.3% | 892 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $24,000 | +4.3% | 892 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $23,000 | +53.3% | 892 | 0.0% | 0.00% | +100.0% |
| Q1 2019 | $15,000 | +50.0% | 892 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $10,000 | – | 892 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |